{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:33:01Z","timestamp":1787106781594,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2508900"],"award-info":[{"award-number":["2023YFC2508900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82170187"],"award-info":[{"award-number":["No. 82170187"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04988-5","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:05:56Z","timestamp":1781251556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Late phase transfusion after CAR T therapy is associated with persistent hematotoxicity and non-relapse mortality in multiple myeloma: a post hoc analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Fan","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuekun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunming","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiling","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"10","key":"4988_CR1","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1016\/S2352-3026(24)00176-5","volume":"11","author":"D Zhou","year":"2024","unstructured":"Zhou D, Sun Q, Xia J, Gu W, Qian J, Zhuang W, et al. Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial. Lancet Haematol. 2024;11(10):e751\u201360.","journal-title":"Lancet Haematol"},{"issue":"20","key":"4988_CR2","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.21.01676","volume":"40","author":"Y Wang","year":"2022","unstructured":"Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z, et al. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. J Clin Oncol. 2022;40(20):2246\u201356.","journal-title":"J Clin Oncol"},{"issue":"14","key":"4988_CR3","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","volume":"42","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, et al. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed\/Refractory Multiple Myeloma. J Clin Oncol. 2024;42(14):1665\u201375.","journal-title":"J Clin Oncol"},{"issue":"20","key":"4988_CR4","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","volume":"133","author":"P Karschnia","year":"2019","unstructured":"Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133(20):2212\u201321.","journal-title":"Blood"},{"issue":"7","key":"4988_CR5","first-page":"438.e1","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, et al. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transpl Cell Ther. 2023;29(7):438.e1-438.e16","journal-title":"Transpl Cell Ther"},{"issue":"5","key":"4988_CR6","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","volume":"146","author":"CW Freyer","year":"2020","unstructured":"Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol. 2020;146(5):940\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"10297","key":"4988_CR7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"8","key":"4988_CR8","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"9","key":"4988_CR9","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas Dos Santos","year":"2024","unstructured":"Cordas Dos Santos DM, Tix T, Shouval R, Gafter-Gvili A, Alberge JB, Cliff ERS, et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024;30(9):2667\u201378.","journal-title":"Nat Med"},{"issue":"10","key":"4988_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, et al. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood. 2023;142(10):865\u201377.","journal-title":"Blood"},{"issue":"5","key":"4988_CR11","doi-asserted-by":"publisher","first-page":"e889","DOI":"10.1097\/HS9.0000000000000889","volume":"7","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Greco R, Onida F, S\u00e1nchez-Ortega I, Bonini C, Sureda A, et al. An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA. Hemasphere. 2023;7(5):e889.","journal-title":"Hemasphere"},{"issue":"7","key":"4988_CR12","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1182\/blood.2025028833","volume":"146","author":"K Rejeski","year":"2025","unstructured":"Rejeski K, Sanz J, Fei T, Nair MS, Hashmi H, Avigdor A, et al. T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy. Blood. 2025;146(7):834\u201346.","journal-title":"Blood"},{"issue":"6","key":"4988_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00262-024-03661-1","volume":"73","author":"S Ma","year":"2024","unstructured":"Ma S, Wang Y, Qi K, Lu W, Qi Y, Cao J, et al. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia. Cancer Immunol Immunother. 2024;73(6):104.","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"4988_CR14","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","volume":"54","author":"S Fried","year":"2019","unstructured":"Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transpl. 2019;54(10):1643\u201350.","journal-title":"Bone Marrow Transpl"},{"issue":"15","key":"4988_CR15","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","volume":"4","author":"T Jain","year":"2020","unstructured":"Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4(15):3776\u201387.","journal-title":"Blood Adv"},{"issue":"3","key":"4988_CR16","doi-asserted-by":"publisher","first-page":"e010687","DOI":"10.1136\/jitc-2024-010687","volume":"13","author":"C Jin","year":"2025","unstructured":"Jin C, Chen R, Fu S, Zhang M, Teng Y, Yang T, et al. Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed\/refractory multiple myeloma. J Immunother Cancer. 2025;13(3):e010687.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"4988_CR17","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/trf.14488","volume":"58","author":"KE Remy","year":"2018","unstructured":"Remy KE, Hall MW, Cholette J, Juffermans NP, Nicol K, Doctor A, et al. Mechanisms of red blood cell transfusion-related immunomodulation. Transfusion. 2018;58(3):804\u201315.","journal-title":"Transfusion"},{"issue":"2","key":"4988_CR18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/jso.20272","volume":"91","author":"JG Shen","year":"2005","unstructured":"Shen JG, Cheong JH, Hyung WJ, Kim J, Choi SH, Noh SH. Pretreatment anemia is associated with poorer survival in patients with stage I and II gastric cancer. J Surg Oncol. 2005;91(2):126\u201330.","journal-title":"J Surg Oncol"},{"issue":"4","key":"4988_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.5230\/jgc.2010.10.4.196","volume":"10","author":"SH Kim","year":"2010","unstructured":"Kim SH, Lee SI, Noh SM. Prognostic significance of preoperative blood transfusion in stomach cancer. J Gastric Cancer. 2010;10(4):196\u2013205.","journal-title":"J Gastric Cancer"},{"key":"4988_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijsu.2014.11.044","volume":"13","author":"C Sun","year":"2015","unstructured":"Sun C, Wang Y, Yao HS, Hu ZQ. Allogeneic blood transfusion and the prognosis of gastric cancer patients: systematic review and meta-analysis. Int J Surg. 2015;13:102\u201310.","journal-title":"Int J Surg"},{"key":"4988_CR21","doi-asserted-by":"publisher","first-page":"976011","DOI":"10.3389\/fimmu.2022.976011","volume":"13","author":"R Mispelbaum","year":"2022","unstructured":"Mispelbaum R, Hattenhauer ST, Brossart P, Heine A. Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumors. Front Immunol. 2022;13:976011.","journal-title":"Front Immunol"},{"issue":"6","key":"4988_CR22","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1182\/bloodadvances.2023011727","volume":"8","author":"S Vic","year":"2024","unstructured":"Vic S, Thibert JB, Bachy E, Cartron G, Gastinne T, Morschhauser F, et al. Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study). Blood Adv. 2024;8(6):1573\u201385.","journal-title":"Blood Adv"},{"issue":"1","key":"4988_CR23","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1080\/07853890.2022.2136748","volume":"54","author":"Y Xia","year":"2022","unstructured":"Xia Y, Zhang J, Li J, Zhang L, Li J, Fan L, et al. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors. Ann Med. 2022;54(1):2951\u201365.","journal-title":"Ann Med"},{"issue":"4","key":"4988_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transpl. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"4988_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J Hematol Oncol. 2023;16(1):88.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4988_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","volume":"26","author":"A Cordeiro","year":"2020","unstructured":"Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, et al. Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. Biol Blood Marrow Transpl. 2020;26(1):26\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"16","key":"4988_CR27","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1182\/bloodadvances.2024015732","volume":"9","author":"JH Frenking","year":"2025","unstructured":"Frenking JH, Zhou X, Rejeski K, Wagner V, Costello P, Hielscher T, et al. Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma. Blood Adv. 2025;9(16):4151\u201366.","journal-title":"Blood Adv"},{"issue":"8","key":"4988_CR28","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","volume":"8","author":"K Rejeski","year":"2024","unstructured":"Rejeski K, Wang Y, Hansen DK, Iacoboni G, Bachy E, Bansal R, et al. Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Adv. 2024;8(8):1857\u201368.","journal-title":"Blood Adv"},{"issue":"24","key":"4988_CR29","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood. 2021;138(24):2499\u2013513.","journal-title":"Blood"},{"issue":"7","key":"4988_CR30","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","volume":"6","author":"KR Juluri","year":"2022","unstructured":"Juluri KR, Wu QV, Voutsinas J, Hou J, Hirayama AV, Mullane E, et al. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv. 2022;6(7):2055\u201368.","journal-title":"Blood Adv"},{"issue":"6","key":"4988_CR31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14737140.2024.2344650","volume":"24","author":"JA Davis","year":"2024","unstructured":"Davis JA, McGann M, Marini J, Hashmi H. How to manage prolonged immune effector cell-associated hematotoxicity (ICAHT) related to BCMA-directed myeloma therapy. Expert Rev Anticancer Ther. 2024;24(6):335\u20138.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"4988_CR32","first-page":"298","volume":"30","author":"JA Davis","year":"2024","unstructured":"Davis JA, Dima D, Ahmed N, DeJarnette S, McGuirk J, Jia X, et al. Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed\/Refractory Multiple Myeloma. Transpl Cell Ther. 2024;30(3):298\u2013305.","journal-title":"Transpl Cell Ther"},{"issue":"Suppl 1","key":"4988_CR33","doi-asserted-by":"publisher","first-page":"e14157","DOI":"10.1111\/tid.14157","volume":"25","author":"E Kampouri","year":"2023","unstructured":"Kampouri E, Little JS, Rejeski K, Manuel O, Hammond SP, Hill JA. Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies. Transpl Infect Dis. 2023;25(Suppl 1):e14157.","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"4988_CR34","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41409-025-02578-2","volume":"60","author":"J Liu","year":"2025","unstructured":"Liu J, Li Y, Zhu F, Lv B, Xu J, Du M, et al. Prior antibiotics exposure predicts early and prolonged CD19 CAR T-cell-related hematologic toxicity and prognosis in acute B-cell leukemia. Bone Marrow Transpl. 2025;60(6):902\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"4988_CR35","doi-asserted-by":"publisher","first-page":"1566016","DOI":"10.3389\/fimmu.2025.1566016","volume":"16","author":"L Yin","year":"2025","unstructured":"Yin L, Lv B, Ge J, Qi Y, Xia J, Ma S, et al. The impact of antibiotic use on outcomes of relapsed\/refractory multiple myeloma patients treated with CAR-T therapy. Front Immunol. 2025;16:1566016.","journal-title":"Front Immunol"},{"issue":"4","key":"4988_CR36","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","volume":"28","author":"M Smith","year":"2022","unstructured":"Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med. 2022;28(4):713\u201323.","journal-title":"Nat Med"},{"issue":"4","key":"4988_CR37","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41591-023-02234-6","volume":"29","author":"CK Stein-Thoeringer","year":"2023","unstructured":"Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med. 2023;29(4):906\u201316.","journal-title":"Nat Med"},{"issue":"7","key":"4988_CR38","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41409-024-02278-3","volume":"59","author":"EC Liang","year":"2024","unstructured":"Liang EC, Rejeski K, Fei T, Albittar A, Huang JJ, Portuguese AJ, et al. Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity. Bone Marrow Transpl. 2024;59(7):910\u20137.","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"4988_CR39","doi-asserted-by":"publisher","first-page":"szaf061","DOI":"10.1093\/stcltm\/szaf061","volume":"14","author":"TM Baumhardt","year":"2025","unstructured":"Baumhardt TM, Amoah A, Hoenicka M, Liebold A, Sakk V, Soller K, et al. Functional and molecular analyses reveal impaired HSPCs in Multiple Myeloma patients post-induction. Stem Cells Transl Med. 2025;14(11):szaf061.","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"4988_CR40","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/bjh.20207","volume":"207","author":"K Chung","year":"2025","unstructured":"Chung K, Ng LS, Yee CI, Bansal R, Kharfan-Dabaja MA, Nowakowski GS, et al. Impact of granulocyte colony-stimulating factor on safety of chimeric antigen receptor-T-cell therapy in non-Hodgkin lymphoma. Br J Haematol. 2025;207(2):606\u201311.","journal-title":"Br J Haematol"},{"issue":"7","key":"4988_CR41","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","volume":"133","author":"RM Sterner","year":"2019","unstructured":"Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133(7):697\u2013709.","journal-title":"Blood"},{"issue":"1","key":"4988_CR42","first-page":"48","volume":"32","author":"MD Winget","year":"2026","unstructured":"Winget MD, Sowell H, Shultes K, Sawyer J, Jayani-Kosarzycki RV, Biltibo E, et al. Impact of Granulocyte Colony Stimulating Factor Use Following CD-19 Chimeric Antigen Receptor T-Cell Therapy. Transpl Cell Ther. 2026;32(1):48\u201358.","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"4988_CR43","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.tmrv.2019.03.001","volume":"33","author":"GI Simon","year":"2019","unstructured":"Simon GI, Craswell A, Thom O, Chew MS, Anstey CM, Fung YL. Impacts of Aging on Anemia Tolerance, Transfusion Thresholds, and Patient Blood Management. Transfus Med Rev. 2019;33(3):154\u201361.","journal-title":"Transfus Med Rev"},{"issue":"Supplement 1","key":"4988_CR44","doi-asserted-by":"publisher","first-page":"12770","DOI":"10.1182\/blood-2022-163457","volume":"140","author":"M Corona De Lapuerta","year":"2022","unstructured":"Corona De Lapuerta M, Shouval R, Alarcon Tomas A, Flynn JR, Devlin SM, Batlevi CL, et al. Severe Persistent Cytopenias Following CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. Blood. 2022;140(Supplement 1):12770\u20132.","journal-title":"Blood"},{"issue":"38","key":"4988_CR45","doi-asserted-by":"publisher","first-page":"eadg3919","DOI":"10.1126\/sciadv.adg3919","volume":"9","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Perez A, Iacoboni G, Blumenberg V, B\u00fccklein VL, V\u00f6lkl S, et al. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci Adv. 2023;9(38):eadg3919.","journal-title":"Sci Adv"},{"issue":"21","key":"4988_CR46","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1182\/bloodadvances.2023012522","volume":"8","author":"ML Palacios-Berraquero","year":"2024","unstructured":"Palacios-Berraquero ML, Rodriguez-Marquez P, Calleja-Cervantes ME, Berastegui N, Zabaleta A, Burgos L, et al. Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma. Blood Adv. 2024;8(21):5479\u201392.","journal-title":"Blood Adv"},{"issue":"4 Suppl 1","key":"4988_CR47","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0887-7963(90)70239-8","volume":"4","author":"N Blumberg","year":"1990","unstructured":"Blumberg N, Triulzi DJ, Heal JM. Transfusion-induced immunomodulation and its clinical consequences. Transfus Med Rev. 1990;4(4 Suppl 1):24\u201335.","journal-title":"Transfus Med Rev"},{"key":"4988_CR48","doi-asserted-by":"publisher","first-page":"103267","DOI":"10.1016\/j.eclinm.2025.103267","volume":"84","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Liu K, Rosen ST, Liu W, Zhu H. Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: a systematic review and meta-analysis. EClinicalMedicine. 2025;84:103267.","journal-title":"EClinicalMedicine"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04988-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04988-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04988-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:01:50Z","timestamp":1787104910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04988-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4988"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04988-5","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University (approval number XYFY2021-KL154-01). Written informed consent was obtained from each patient before study entry in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"453"}}